RxDoctor Payments Data

John Boyle, MD

Ophthalmology · Metairie, LANPI 1225177009

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,772, 2.3 times the $760 reported in 2019.

$7,102in general payments, 2019–2025

Across 281 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Johnson & Johnson Surgical Vision, Inc.$715
  • Glaukos Corporation$544
  • AbbVie$523
  • Tarsus Pharmaceuticals, Inc.$517
  • Rxsight Inc$411
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$7,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,102 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$298,178
Medicare patients
840
Services billed
2,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost281$124,033
LumiganBimatoprost202$68,574
RestasisCyclosporine82$67,018
CombiganBrimonidine Tartrate/Timolol222$66,183
XdemvyLotilaner31$58,504
RhopressaNetarsudil Mesylate108$43,051
TyrvayaVarenicline Tartrate41$29,206
Latanoprost2,403$18,518
Alphagan PBrimonidine Tartrate50$17,564
SimbrinzaBrinzolamide/Brimonidine Tart62$16,399
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,062$15,787
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol138$15,691
XiidraLifitegrast23$15,367
Prednisolone Acetate480$14,435
IlevroNepafenac32$12,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$523$219,339556 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$68$167,083389 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$517$58,50431 claims
Oyster Point Pharma, Inc.Tyrvaya$324$29,20641 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$227$24,07849 claims
AlconSimbrinza$1,562$16,39962 claims
NovartisIlevro$30$12,06332 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$67$8,09031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →